Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

56 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Longitudinal blood immune-inflammatory and radiomic profiling to decode different patterns of acquired resistance to immunotherapy in patients with NSCLC.
Mazzaschi G, Marrocchio C, Moron Dalla Tor L, Leo L, Balbi M, Milanese G, Adebanjo GAR, Lorusso B, Monica G, Pluchino M, Minari R, D'Agnelli S, Cardinale E, Perrone F, Bordi P, Leonetti A, Ledda RE, Silva M, Buti S, Roti G, Bettati S, Quaini F, Tiseo M, Sverzellati N. Mazzaschi G, et al. Clin Cancer Res. 2024 Dec 13. doi: 10.1158/1078-0432.CCR-24-1926. Online ahead of print. Clin Cancer Res. 2024. PMID: 39670974
Non-homogenous intratumor ionizing radiation doses synergize with PD1 and CXCR2 blockade.
Bergeron P, Dos Santos M, Sitterle L, Tarlet G, Lavigne J, Liu W, Gerbé de Thoré M, Clémenson C, Meziani L, Schott C, Mazzaschi G, Berthelot K, Benadjaoud MA, Milliat F, Deutsch E, Mondini M. Bergeron P, et al. Among authors: mazzaschi g. Nat Commun. 2024 Oct 14;15(1):8845. doi: 10.1038/s41467-024-53015-9. Nat Commun. 2024. PMID: 39397001 Free PMC article.
Development and validation of a new tool to estimate early mortality in patients with advanced cancer treated with immunotherapy.
De Giglio A, Leonetti A, Comito F, Filippini DM, Mollica V, Rihawi K, Peroni M, Mazzaschi G, Ricciotti I, Carosi F, Marchetti A, Rosellini M, Gagliano A, Favorito V, Nobili E, Gelsomino F, Melotti B, Marchese PV, Sperandi F, Di Federico A, Buti S, Perrone F, Massari F, Pantaleo MA, Tiseo M, Ardizzoni A. De Giglio A, et al. Among authors: mazzaschi g. Cancer Immunol Immunother. 2024 Oct 3;73(12):246. doi: 10.1007/s00262-024-03836-w. Cancer Immunol Immunother. 2024. PMID: 39358642 Free PMC article.
Liquid Biopsy and 18F-FDG PET/CT Derived Parameters as Predictive Factors of Osimertinib Treatment in Advanced EGFR-Mutated NSCLC.
Leonetti A, Cervati V, Minari R, Scarlattei M, Verzè M, Peroni M, Pluchino M, Bonatti F, Perrone F, Mazzaschi G, Cosenza A, Gnetti L, Bordi P, Ruffini L, Tiseo M. Leonetti A, et al. Among authors: mazzaschi g. Clin Lung Cancer. 2024 Dec;25(8):e436-e445.e9. doi: 10.1016/j.cllc.2024.07.016. Epub 2024 Aug 6. Clin Lung Cancer. 2024. PMID: 39198088
Longitudinal Changes of CT-radiomic and Systemic Inflammatory Features Predict Survival in Advanced Non-Small Cell Lung Cancer Patients Treated With Immune Checkpoint Inhibitors.
Balbi M, Mazzaschi G, Leo L, Moron Dalla Tor L, Milanese G, Marrocchio C, Silva M, Mura R, Favia P, Bocchialini G, Trentini F, Minari R, Ampollini L, Quaini F, Roti G, Tiseo M, Sverzellati N. Balbi M, et al. Among authors: mazzaschi g. J Thorac Imaging. 2025 Jan 1;40(1):e0801. doi: 10.1097/RTI.0000000000000801. J Thorac Imaging. 2025. PMID: 39188157 Free PMC article.
A red blood cell-based score in the prognostication of patients with metastatic RCC of the Meet-URO 15 study.
Anpalakhan S, Banna GL, Rebuzzi SE, Fornarini G, Maruzzo M, Zucali PA, Catalano F, Antonj L, Tudini M, Fratino L, Malgeri A, Rescigno P, Signori A, Acunzo A, Silini EM, Mazzaschi G, Buti S. Anpalakhan S, et al. Among authors: mazzaschi g. Immunotherapy. 2024;16(14-15):963-973. doi: 10.1080/1750743X.2024.2382666. Epub 2024 Aug 6. Immunotherapy. 2024. PMID: 39105621
Differential impact of lipid profile according to neutrophil-to-lymphocyte ratio status in patients with advanced cancer treated with immunotherapy.
Perrone F, Pecci F, Maffezzoli M, Giudice GC, Cognigni V, Mazzaschi G, Cantini L, Santamaria L, Paoloni F, Bruno Rocchi ML, Coriano' M, Acunzo A, Quaini F, Tiseo M, Kamal SS, Berardi R, Buti S. Perrone F, et al. Among authors: mazzaschi g. Immunotherapy. 2024;16(13):859-868. doi: 10.1080/1750743X.2024.2377953. Epub 2024 Aug 6. Immunotherapy. 2024. PMID: 39105618
Intersecting Blood Cytokines With Cholesterol Parameters to Profile Patients With Advanced Solid Tumors Receiving Immune Checkpoint Inhibitors.
Mazzaschi G, Perrone F, Maglietta G, Favari E, Verzè M, Pluchino M, Minari R, Pecci F, Gnetti L, Campanini N, Silini EM, De Filippo M, Maffezzoli M, Giudice GC, Testi I, Tiseo M, Quaini F, Buti S. Mazzaschi G, et al. J Immunother. 2024 Nov-Dec 01;47(9):388-394. doi: 10.1097/CJI.0000000000000534. Epub 2024 Jul 11. J Immunother. 2024. PMID: 38989743 Free PMC article.
Immunomodulatory effects of antiangiogenic tyrosine kinase inhibitors in renal cell carcinoma models: Impact on following anti-PD-1 treatments.
Fumarola C, La Monica S, Bonelli M, Zoppi S, Alfieri R, Galetti M, Gnetti L, Campanini N, Pozzi G, Cavazzoni A, Mazzaschi G, Silini EM, Buti S, Petronini PG. Fumarola C, et al. Among authors: mazzaschi g. Biochem Pharmacol. 2024 Aug;226:116397. doi: 10.1016/j.bcp.2024.116397. Epub 2024 Jun 27. Biochem Pharmacol. 2024. PMID: 38944394 Free article.
56 results